达伯舒-话题@MedSci - 梅斯（MedSci）

#达伯舒#

6篇内容 | 1090人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1618279, encodeId=341016182e9f0, content=<a href='/topic/show?id=b57793913fe' target=_blank style='color:#2F92EE;'>#达伯舒#</a>, objectTitle=礼来制药与信达生物共同宣布达伯舒®（信迪利单抗注射液）非鳞状非小细胞肺癌一线治疗新适应症正式上市, objectType=article, longId=207677, objectId=f31920e677cb, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f31920e677cb, replyNumber=0, likeNumber=97, createdTime=2021-02-28, rootId=0, userName=ms7019579240139182, userId=390619877096, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f31920e677cb, moduleTitle=礼来制药与信达生物共同宣布达伯舒®（信迪利单抗注射液）非鳞状非小细胞肺癌一线治疗新适应症正式上市, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=f31920e677cb)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1618278, encodeId=13ad16182e8b1, content=<a href='/topic/show?id=b57793913fe' target=_blank style='color:#2F92EE;'>#达伯舒#</a>, objectTitle=2020 WCLC：达伯舒®（信迪利单抗注射液）联合化疗一线治疗非鳞状非小细胞肺癌III期数据喜人, objectType=article, longId=199076, objectId=63ee1990e68c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=63ee1990e68c, replyNumber=0, likeNumber=72, createdTime=2020-08-11, rootId=0, userName=ms7019579240139182, userId=390619877096, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=63ee1990e68c, moduleTitle=2020 WCLC：达伯舒®（信迪利单抗注射液）联合化疗一线治疗非鳞状非小细胞肺癌III期数据喜人, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=63ee1990e68c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1618277, encodeId=7f4216182e7d0, content=<a href='/topic/show?id=b57793913fe' target=_blank style='color:#2F92EE;'>#达伯舒#</a>, objectTitle=达伯舒®联合抗VEGF单抗用于一线HCC的研究完成首例患者给药, objectType=article, longId=161437, objectId=0fed16143ef7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0fed16143ef7, replyNumber=0, likeNumber=81, createdTime=2019-03-02, rootId=0, userName=ms7019579240139182, userId=390619877096, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0fed16143ef7, moduleTitle=达伯舒®联合抗VEGF单抗用于一线HCC的研究完成首例患者给药, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=0fed16143ef7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1618276, encodeId=4ed616182e692, content=<a href='/topic/show?id=b57793913fe' target=_blank style='color:#2F92EE;'>#达伯舒#</a>, objectTitle=信达生物宣布达伯舒®一线胃癌III期临床研究完成首例患者给药, objectType=article, longId=158309, objectId=2e6815830948, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2e6815830948, replyNumber=0, likeNumber=81, createdTime=2019-01-19, rootId=0, userName=ms7019579240139182, userId=390619877096, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2e6815830948, moduleTitle=信达生物宣布达伯舒®一线胃癌III期临床研究完成首例患者给药, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=2e6815830948)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1618275, encodeId=579c16182e5d4, content=<a href='/topic/show?id=b57793913fe' target=_blank style='color:#2F92EE;'>#达伯舒#</a>, objectTitle=我国自主研发抗癌新药达伯舒获准上市，价格将低于同类进口药, objectType=article, longId=157612, objectId=611715e61263, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=611715e61263, replyNumber=0, likeNumber=79, createdTime=2019-01-10, rootId=0, userName=ms7019579240139182, userId=390619877096, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=611715e61263, moduleTitle=我国自主研发抗癌新药达伯舒获准上市，价格将低于同类进口药, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=611715e61263)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1618274, encodeId=3f1116182e4df, content=<a href='/topic/show?id=b57793913fe' target=_blank style='color:#2F92EE;'>#达伯舒#</a>, objectTitle=抗PD-1单克隆抗体达伯舒®（信迪利单抗注射液）在中国正式获批, objectType=article, longId=156858, objectId=0ef515685842, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0ef515685842, replyNumber=0, likeNumber=84, createdTime=2018-12-29, rootId=0, userName=ms7019579240139182, userId=390619877096, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0ef515685842, moduleTitle=抗PD-1单克隆抗体达伯舒®（信迪利单抗注射液）在中国正式获批, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=0ef515685842)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

达伯舒

2020-05-29

ms7019579240139182 (审核中...)

前往app查看评论内容

#达伯舒#

礼来制药与信达生物共同宣布达伯舒®（信迪利单抗注射液）非鳞状非小细胞肺癌一线治疗新适应症正式上市

2021-02-28

ms7019579240139182 (审核中...)

前往app查看评论内容

#达伯舒#

2020 WCLC：达伯舒®（信迪利单抗注射液）联合化疗一线治疗非鳞状非小细胞肺癌III期数据喜人

2020-08-11

ms7019579240139182 (审核中...)

前往app查看评论内容

#达伯舒#

达伯舒®联合抗VEGF单抗用于一线HCC的研究完成首例患者给药

2019-03-02

ms7019579240139182 (审核中...)

前往app查看评论内容

#达伯舒#

信达生物宣布达伯舒®一线胃癌III期临床研究完成首例患者给药

2019-01-19

ms7019579240139182 (审核中...)

前往app查看评论内容

#达伯舒#

我国自主研发抗癌新药达伯舒获准上市，价格将低于同类进口药

2019-01-10

ms7019579240139182 (审核中...)

前往app查看评论内容

#达伯舒#

抗PD-1单克隆抗体达伯舒®（信迪利单抗注射液）在中国正式获批

2018-12-29

科室
- - 订阅+
  - 更多科室
工具
服务